Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

538

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GLIMEPIRIDE

"Pharmaceutical form: oral~Route of administration: oral"

DRUG

METFORMIN

"Pharmaceutical form: oral~Route of administration: oral"

Trial Locations (55)

170

Investigational Site Number 170001, Manizales

2070

Investigational Site Number 78803, La Marsa

Investigational Site Number 78804, La Marsa

4091

Investigational Site Number 710-002, Durban

4092

Investigational Site Number 710-001, Durban

19000

Investigational Site Number 01205, Sétif

31000

Investigational Site Number 01203, Oran

34722

Investigational Site Number 792-001, Istanbul

34890

Investigational Site Number 792-006, Istanbul

44340

Investigational Site Number 484002, Guadalajara

44670

Investigational Site Number 484003, Guadalajara

46458

Investigational Site Number 784-004, Sharjah city

58140

Investigational Site Number 792-005, Sivas

119002

Investigational Site Number 643003, Moscow

226003

Investigational Site Number 356009, Lucknow

410012

Investigational Site Number 643002, Saratov

411007

Investigational Site Number 356008, Pune

422002

Investigational Site Number 356007, Nashik

452010

Investigational Site Number 356003, Indore

560043

Investigational Site Number 356001, Bangalore

560052

Investigational Site Number 356002, Bangalore

1411413137

Investigational Site Number 364001, Tehran

1666694516

Investigational Site Number 364002, Tehran

Unknown

Investigational Site Number 01206, Algeries

Investigational Site Number 17003, El Espinal

Investigational Site Number 81801, Cairo

Investigational Site Number 81802, Cairo

Investigational Site Number 81803, Cairo

Investigational Site Number 32001, Guatemala City

Investigational Site Number 32002, Guatemala City

Investigational Site Number 32003, Guatemala City

Investigational Site Number 32004, Guatemala City

Investigational Site Number 356006, Ernākulam

Investigational Site Number 356010, Mumbai

Investigational Site Number 356005, Varanasi

Investigational Site Number 36403, Tehran

Investigational Site Number 42201, Beirut

Investigational Site Number 42202, Beirut

Investigational Site Number 42203, Chouf

Investigational Site Number 422004, Hazmiyeh

Investigational Site Number 643001, Saint Petersburg

Investigational Site Number 78805, Sfax

Investigational Site Number 78801, Tunis

Investigational Site Number 78802, Tunis

Investigational Site Number 78806, Tunis

Investigational Site Number 78807, Tunis

Investigational Site Number 792-004, Adana

Investigational Site Number 792-002, Kütahya

Investigational Site Number 804003, Zaporizhzhya

Investigational Site Number 784-001, Dubai

Investigational Site Number 784-002, Dubai

Investigational Site Number 784-003, Dubai

07070

Investigational Site Number 792-003, Antalya

02175

Investigational Site Number 804001, Kyiv

04114

Investigational Site Number 804002, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY